KEYMAKER-U01 Substudy 01G: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab With or Without Platinum-based Chemotherapy in Treatment-Naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)

Summary

Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical removal. Standard treatments include immunotherapy, such as pembrolizumab, and chemotherapy. This study aims to determine the effectiveness of adding other treatments, including the human epidermal growth factor receptor 3-directed antibody-drug conjugate (HER3-DXd) patritumab deruxtecan, to pembrolizumab, with or without chemotherapy. The primary goals are to assess safety and efficacy of the treatments.

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Biological
  Pembrolizumab

  Pembrolizumab 200mg IV Infusion.

• Drug
  Carboplatin

  Carboplatin IV infusion AUC5 or 6 mg/mL•min and not exceeding 900mg.

• Drug
  Paclitaxel

  Paclitaxel 200 mg/m\^2 IV infusion.

• Drug
  Nab-paclitaxel

  Nab-paclitaxel 100mg/m\^2 IV infusion.

• Drug
  Pemetrexed

  Pemetrexed 500mg/m\^2 IV infusion.

• Biological
  HER3-DXd

  HER3-Dxd 5.6mg/kg IV infusion.

Locations (41)